Hepatitis A virus (HAV) and hepatitis E virus (HEV) are thought to have similar routes of transmission and epidemiology in developing countries. This study investigated the seroprevalences of these pathogens among healthy individuals in the Dhanusha district of Madesh Province, Nepal. Ninety serum samples collected between 2022 and 2023 were analyzed by enzyme-linked immunosorbent assay to detect immunoglobulin (Ig)G antibodies against HAV and HEV. Individuals (median age, 23 years; range, 1-45 years) were sorted into five age groups: 1-10, 11-20, 21-30, 31-40 and 41-45 years. Prevalences of HAV and HEV IgGs were 96.7% and 13.3%, respectively. All age groups showed very high positivity rates for HAV antibodies. In contrast, HEV infection rates were extremely low in children, and rapidly increased in adults >31 years old. No significant correlation was found between HAV and HEV seropositivity. Additional studies including other areas in Nepal are required for nationwide sero-surveillance against HAV and HEV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7883/yoken.JJID.2024.321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways.
Hepatol Commun
April 2025
Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Background: Autophagic and endosomal pathways coordinately contribute to HBV virions and subviral particles (SVPs) production. To date, limited evidence supports that HBV and exosomes have a common pathway for their biogenesis and secretion. The final steps of HBV production and release have not yet been well studied.
View Article and Find Full Text PDFSince 2022, cases of hepatitis of unknown origin have been reported in children worldwide. Adeno-associated virus type 2 (AAV2) was identified as a cause, with most affected children having the HLA-DRB1 04:01 genotype. In this study, we hypothesized that HLA-DRB1 04:01 in the host may also be a potential predisposing factor of acute hepatitis caused by other viruses.
View Article and Find Full Text PDFVirological response and predictive factors for antiviral treatment in chronic HBV-related liver disease with low ALT and high HBV DNA.
Front Immunol
March 2025
Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Objective: To investigate virological response and predictive factors for antiviral treatment in chronic HBV patients with low ALT and high HBV DNA.
Methods: A retrospective study grouped chronic HBV patients by baseline ALT: ALT > 80 U/L (significantly elevated group, SAG), 40-80 U/L (mildly elevated group, MAG), and ≤ 40 U/L (normal group, NG). Inverse probability treatment weighting balanced confounding factors.
Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma.
Therap Adv Gastroenterol
March 2025
Department of Gastroenterology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving survival rates.
Objectives: We analyzed the impact of eradication by interferon (IFN)-free direct-acting antiviral (DAA) therapy on clinical outcomes of patients with HCV-associated HCC who underwent curative treatment.
Design: This was a retrospective study.
Effectiveness and Safety of Tenofovir Amibufenamide in the Treatment of Chronic Hepatitis B: A Real-world, Multicenter Study.
J Clin Transl Hepatol
March 2025
Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi, China.
Background And Aims: Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management. This study aimed to evaluate the real-world effectiveness and safety of tenofovir amibufenamide (TMF) in a cohort of patients with chronic hepatitis B (CHB).
Methods: In this multicenter, prospective, real-world cohort study, 194 CHB patients were recruited from four hospitals between August 2021 and August 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!